Introduction
Drägerwerk AG & Co. KGaA, a leading provider of medical and safety technology, has experienced impressive stock performance over the past few months. Despite current fluctuations, the stock shows a year-to-date increase of over 36 percent, indicating a positive market trend and sustained investor confidence. Here are some key aspects that shed light on the current situation of Drägerwerk shares:
Current Developments
- Dividend Policy: Drägerwerk plans to increase its dividend for the year 2024. The management board proposes a payout of €1.97 per ordinary share and €2.03 per preference share. This decision is part of a strategy to distribute at least 30 percent of the group’s earnings to shareholders, provided that the equity ratio is at least 40 percent.
- Business Development: In the financial year 2024, Drägerwerk achieved sales of nearly €3.4 billion, although the earnings before interest and taxes (EBIT) increased by more than 16 percent to €194 million.
- Stock Performance: The Drägerwerk stock has seen a remarkable increase in value of almost 42 percent since the beginning of the year and reached its 52-week high in March 2025.
Analyst Opinions and Recommendations
- Analyst Recommendations: Many analysts recommend buying Drägerwerk stock. For instance, Warburg Research has issued a “Buy” rating. Other analysts have also provided buy recommendations.
- Price Targets: Experts set an average price target of approximately €62.67. Some analysts even see higher targets.
Innovation and Product Development
- New Products: Drägerwerk has announced the launch of the software solution BiliPredics, which expands the existing offerings in neonatal care. This innovation underscores the company’s ongoing capacity for innovation.
Overall, Drägerwerk demonstrates solid business development and a positive outlook, which is also reflected in the dividend increase and continued support from analysts.